ArticleAnnals of medicine and surgery (2012)2025
A case of familial hypertriglyceridemia associated with a novel heterozygous AGPAT2 mutation.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and importance: Severe hypertriglyceridemia is increasingly leading to referrals to endocrinology clinics. Patients commonly present with clinical manifestations such as recurrent abdominal pain, acute pancreatitis, and eruptive xanthomas. Case presentation: We report the case of a young male patient with over 30 recurrent episodes of acute pancreatitis and extremely elevated triglyceride levels. Genetic testing identified a heterozygous pathogenic mutation in the 1-acylglycerol-3-phosphate-o-acetyltransferase 2 (AGPAT2) gene. Further deletion/duplication analysis of the AGPAT2 gene was negative. The clinical presentation closely resembled type I hyperlipoproteinemia. Clinical discussion: Despite the typical presentation of type I hyperlipoproteinemia, the identification of a heterozygous AGPAT2 mutation suggests a potential novel genetic contributor to familial hypertriglyceridemia. This finding highlights the importance of genetic analysis in understanding atypical presentations of hyperlipoproteinemia and underscores the need to explore this mutation's inheritance patterns and pathophysiological implications. Conclusion: The heterozygous AGPAT2 mutation may represent a novel genetic factor in familial hypertriglyceridemia. Further research is needed to clarify its clinical significance and inheritance mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.